News & Updates
Filter by Specialty:
Immunosuppression treatment with mTORi carries risk of ovarian cyst
Among women receiving immunosuppression treatment with mammalian target of rapamycin inhibitors (mTORi), the incidence of ovarian cyst appears to be a common adverse event, according to the results of a systematic review and meta-analysis.
Immunosuppression treatment with mTORi carries risk of ovarian cyst
06 Oct 2021
Adaptive vs conventional deep-brain stimulation offers advantages for Parkinson’s disease
A small open-label study supports the safety and motor performance effectiveness of closed-loop adaptive deep-brain stimulation (aDBS) compared with conventional daily deep-brain stimulation (cDBS) sessions in Parkinson’s disease (PD) patients.
Adaptive vs conventional deep-brain stimulation offers advantages for Parkinson’s disease
06 Oct 2021
Extended letrozole therapy improves DFS in postmenopausal women with breast cancer
Extending treatment with letrozole for 5 years improves disease-free survival (DFS) rates in postmenopausal women with early-stage breast cancer who have already received tamoxifen for 2–3 years, according to the GIM4* trial.
Extended letrozole therapy improves DFS in postmenopausal women with breast cancer
06 Oct 2021
Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
In the treatment of women with acute ischaemic stroke, mechanical thrombectomy is effective and can be safely performed during pregnancy or the postpartum period, as shown in a study.
Thrombectomy a viable first-line therapy for stroke in pregnant women, new mothers
05 Oct 2021
Delgocitinib ointment safely reduces symptoms in paediatric atopic dermatitis
Treatment with delgocitinib ointment, a topical Janus kinase (JAK) inhibitor, for paediatric atopic dermatitis (AD) is effective and well tolerated when applied for up to 56 weeks, according to a phase III trial and a subsequent open-label, long-term study in Japan.